Recent Posts

Powered by CIRM Grant, jCyte Launches New Clinical Trial April 19, 2017 - Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy   April 19, 2017 – Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of Read More >
Retinitis Pigmentosa Therapy Highlighted at CIRM Symposium April 3, 2017 - The California Institute for Regenerative Medcine's (CIRM's) second annual Alpha Stem Cell Clinics Network symposium showcased how stem cell therapies are rapidly moving towards the clinic. One of our co-founders, Dr. Henry Klassen, spoke about Read More >
CIRM Grant Sets Stage for Next Clinical Trial January 5, 2017 - Developing groundbreaking therapies can be maddeningly slow, but jCyte recently took a big step forward, receiving an $8.3 million grant from the California Institute for Regenerative Medicine (CIRM) to help fund a phase 2b trial Read More >